Cero Therapeutics Holdings, Inc. SEC filings CEROW
Cero Therapeutics Holdings, Inc. has 445 filings in SEC EDGAR's recent list, going back to Jul 8, 2021. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 7, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Aug 14, 2026 | — |
| 424B3 | Prospectus | Jul 17, 2026 | — |
| 424B3 | Prospectus | Jun 26, 2026 | — |
| 424B3 | Prospectus | May 29, 2026 | — |
| 424B3 | Prospectus | May 15, 2026 | — |
| 424B3 | Prospectus | May 1, 2026 | — |
| 424B3 | Prospectus | May 1, 2026 | — |
| 424B3 | Prospectus | Apr 15, 2026 | — |
| 424B3 | Prospectus | Apr 14, 2026 | — |
| 424B3 | Prospectus | Mar 11, 2026 | — |
| 424B3 | Prospectus | Feb 20, 2026 | — |
| 424B3 | Prospectus | Feb 4, 2026 | — |
| 424B3 | Prospectus | Feb 3, 2026 | — |
| 424B3 | Prospectus | Jan 8, 2026 | — |
| 424B3 | Prospectus | Dec 19, 2025 | — |
| S-1 | Registration statement | Dec 5, 2025 | — |
| 424B3 | Prospectus | Dec 2, 2025 | — |
| 424B3 | Prospectus | Dec 2, 2025 | — |
| 424B3 | Prospectus | Nov 20, 2025 | — |
| 424B3 | Prospectus | Nov 20, 2025 | — |
| 424B3 | Prospectus | Oct 30, 2025 | — |
| 424B3 | Prospectus | Oct 30, 2025 | — |
| 424B3 | Prospectus | Oct 23, 2025 | — |
| 424B3 | Prospectus | Oct 23, 2025 | — |
| 424B3 | Prospectus | Sep 5, 2025 | — |
| 424B3 | Prospectus | Sep 5, 2025 | — |
| 424B3 | Prospectus | Sep 4, 2025 | — |
| 424B3 | Prospectus | Sep 4, 2025 | — |
| 424B3 | Prospectus | Aug 22, 2025 | — |
| 424B3 | Prospectus | Aug 22, 2025 | — |
| S-3 | Shelf registration | Aug 11, 2025 | — |
| S-8 | Employee stock plan registration | Jul 28, 2025 | — |
| 424B3 | Prospectus | Jul 25, 2025 | — |
| S-1 | Registration statement | Jul 21, 2025 | — |
| 424B3 | Prospectus | Jul 14, 2025 | — |
| 424B3 | Prospectus | Jul 2, 2025 | — |
| 424B3 | Prospectus | Jun 25, 2025 | — |
| 424B3 | Prospectus | Jun 16, 2025 | — |
| 424B3 | Prospectus | Jun 6, 2025 | — |
| POS AM | Post-effective amendment no. 1 to form s-1 | May 27, 2025 | — |
| 424B3 | Prospectus | Feb 13, 2025 | — |
| 424B3 | Prospectus | Feb 13, 2025 | — |
| 424B3 | Prospectus | Feb 13, 2025 | — |
| 424B3 | Prospectus | Feb 13, 2025 | — |
| 424B3 | Prospectus | Feb 7, 2025 | — |
| S-1/A | Amended registration statement | Feb 5, 2025 | — |
| 424B3 | Prospectus | Jan 23, 2025 | — |
| 424B3 | Prospectus | Jan 23, 2025 | — |
| 424B3 | Prospectus | Jan 23, 2025 | — |
| 424B3 | Prospectus | Jan 23, 2025 | — |
| S-1/A | Amended registration statement | Jan 21, 2025 | — |
| 424B3 | Prospectus | Jan 14, 2025 | — |
| 424B3 | Prospectus | Jan 14, 2025 | — |
| 424B3 | Prospectus | Jan 14, 2025 | — |
| 424B3 | Prospectus | Jan 14, 2025 | — |
| 424B3 | Prospectus | Jan 7, 2025 | — |
| 424B3 | Prospectus | Jan 7, 2025 | — |
| 424B3 | Prospectus | Jan 7, 2025 | — |
| 424B3 | Prospectus | Jan 7, 2025 | — |
| 424B3 | Prospectus | Jan 3, 2025 | — |
| 424B3 | Prospectus | Jan 3, 2025 | — |
| 424B3 | Prospectus | Jan 3, 2025 | — |
| S-1 | Registration statement | Dec 23, 2024 | — |
| S-8 | Employee stock plan registration | Dec 9, 2024 | — |
| 424B3 | Prospectus | Dec 5, 2024 | — |
| 424B3 | Prospectus | Dec 5, 2024 | — |
| S-1 | Registration statement | Nov 27, 2024 | — |
| S-1/A | Amended registration statement | Nov 25, 2024 | — |
| 424B3 | Prospectus | Nov 20, 2024 | — |
| 424B3 | Prospectus | Nov 20, 2024 | — |
| 424B3 | Prospectus | Nov 19, 2024 | — |
| 424B3 | Prospectus | Nov 19, 2024 | — |
| 424B3 | Prospectus | Nov 12, 2024 | — |
| 424B3 | Prospectus | Nov 12, 2024 | — |
| 424B3 | Prospectus | Nov 1, 2024 | — |
| 424B3 | Prospectus | Nov 1, 2024 | — |
| S-1/A | Amended registration statement | Oct 22, 2024 | — |
| S-1 | Registration statement | Oct 21, 2024 | — |
| 424B3 | Prospectus | Oct 21, 2024 | — |
| 424B3 | Prospectus | Oct 21, 2024 | — |
| 424B3 | Prospectus | Oct 11, 2024 | — |
| 424B3 | Prospectus | Oct 11, 2024 | — |
| 424B3 | Prospectus | Oct 4, 2024 | — |
| 424B3 | Prospectus | Oct 4, 2024 | — |
| 424B3 | Prospectus | Sep 26, 2024 | — |
| 424B3 | Prospectus | Sep 26, 2024 | — |
| 424B3 | Prospectus | Aug 2, 2024 | — |
| 424B3 | Prospectus | Aug 2, 2024 | — |
| 424B3 | Prospectus | Jul 8, 2024 | — |
| S-1/A | Amended registration statement | Jun 27, 2024 | — |
| S-1/A | Amended registration statement | Jun 5, 2024 | — |
| 424B3 | Prospectus | May 22, 2024 | — |
| S-1 | Registration statement | May 6, 2024 | — |
| 424B5 | Prospectus supplement | May 1, 2024 | — |
| S-1/A | Amended registration statement | Apr 26, 2024 | — |
| S-1 | Registration statement | Apr 10, 2024 | — |
| 424B3 | Prospectus | Feb 6, 2024 | — |
| 424B3 | Prospectus | Jan 22, 2024 | — |
| S-4/A | Registration statement | Jan 17, 2024 | — |
| S-4/A | Registration statement | Jan 9, 2024 | — |
| S-4/A | Amendment no. 3 to form s-4 | Dec 18, 2023 | — |
| S-4/A | Registration statement | Aug 14, 2023 | — |
| S-4/A | Registration statement | Jul 19, 2023 | — |
| S-4 | Registration for a merger or exchange | Jun 7, 2023 | — |
| 424B4 | Prospectus | Oct 8, 2021 | — |
| S-1/A | Amended registration statement | Sep 28, 2021 | — |
| S-1/A | Amended registration statement | Sep 21, 2021 | — |
| S-1 | Registration statement | Sep 13, 2021 | — |
Showing 108 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CERO (OTC), CEROW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1870404
- Former names
- CERO THERAPEUTICS HOLDINGS, INC. (until Oct 7, 2026); PHOENIX BIOTECH ACQUISITION CORP. (until Feb 14, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.